Epixis SA is a biotechnology company that develops a platform technology for a new generation of Virus-Like Particle vaccines, called “eVLP”. eVLPs have been designed to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV.

Company was acquired by VBI Vaccines